Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 4
1975 1
1976 1
1977 2
1979 3
1980 5
1981 6
1983 3
1984 2
1985 5
1986 9
1987 6
1988 8
1989 2
1990 6
1991 4
1992 7
1993 9
1994 3
1995 8
1996 3
1997 3
1998 11
1999 3
2000 14
2001 14
2002 22
2003 21
2004 24
2005 30
2006 30
2007 38
2008 44
2009 56
2010 51
2011 60
2012 40
2013 59
2014 63
2015 87
2016 97
2017 91
2018 95
2019 97
2020 117
2021 156
2022 186
2023 196
2024 63

Text availability

Article attribute

Article type

Publication date

Search Results

1,673 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Chalbani
Page 1
Resistance to ceftazidime-avibactam and underlying mechanisms.
Wang Y, Wang J, Wang R, Cai Y. Wang Y, et al. J Glob Antimicrob Resist. 2020 Sep;22:18-27. doi: 10.1016/j.jgar.2019.12.009. Epub 2019 Dec 19. J Glob Antimicrob Resist. 2020. PMID: 31863899 Free article. Review.
The resistance to CAZ-AVI exceeds 50% in Acinetobacter baumannii. A higher resistance rate to CAZ-AVI is associated with carbapenem resistance. ...For CAZ-AVI-resistant strains, other effective antibacterial agents or CAZ-AVI in combination with other …
The resistance to CAZ-AVI exceeds 50% in Acinetobacter baumannii. A higher resistance rate to CAZ-AVI is associated with carba …
Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.
Tumbarello M, Raffaelli F, Giannella M, Mantengoli E, Mularoni A, Venditti M, De Rosa FG, Sarmati L, Bassetti M, Brindicci G, Rossi M, Luzzati R, Grossi PA, Corona A, Capone A, Falcone M, Mussini C, Trecarichi EM, Cascio A, Guffanti E, Russo A, De Pascale G, Tascini C, Gentile I, Losito AR, Bussini L, Corti G, Ceccarelli G, Corcione S, Compagno M, Giacobbe DR, Saracino A, Fantoni M, Antinori S, Peghin M, Bonfanti P, Oliva A, De Gasperi A, Tiseo G, Rovelli C, Meschiari M, Shbaklo N, Spanu T, Cauda R, Viale P. Tumbarello M, et al. Clin Infect Dis. 2021 Nov 2;73(9):1664-1676. doi: 10.1093/cid/ciab176. Clin Infect Dis. 2021. PMID: 33618353 Free article.
Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. RESULTS: The cohort comprised 577 adults with bloodstream infections (n = 391) or nonbacteremic infections involving mainly the urinary tract, lower re …
Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. RESULTS: Th …
Update of clinical application in ceftazidime-avibactam for multidrug-resistant Gram-negative bacteria infections.
Zhen S, Wang H, Feng S. Zhen S, et al. Infection. 2022 Dec;50(6):1409-1423. doi: 10.1007/s15010-022-01876-x. Epub 2022 Jul 4. Infection. 2022. PMID: 35781869 Review.
The aim of this review is to describe the recent real-world experience of CAZ-AVI for the infections due to MDR-GNB. METHODS: We searched PubMed, Embase and Google Scholar for clinical application in CAZ-AVI for MDR-GNB infections. ...CONCLUSIONS: CAZ-AVI app …
The aim of this review is to describe the recent real-world experience of CAZ-AVI for the infections due to MDR-GNB. METHODS: We sear …
Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Falcone M, Daikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, Leonildi A, Tagliaferri E, Barnini S, Sani S, Farcomeni A, Ghiadoni L, Menichetti F. Falcone M, et al. Clin Infect Dis. 2021 Jun 1;72(11):1871-1878. doi: 10.1093/cid/ciaa586. Clin Infect Dis. 2021. PMID: 32427286
BACKGROUND: In vitro data support the use of combination of aztreonam (ATM) with ceftazidime-avibactam (CAZ-AVI), but clinical studies are lacking. The aim of our study was to compare the outcome of patients with bloodstream infections (BSIs) due to metallo-beta-lactamase …
BACKGROUND: In vitro data support the use of combination of aztreonam (ATM) with ceftazidime-avibactam (CAZ-AVI), but clinical studie …
Efficacy and safety of ceftazidime-avibactam compared to other antimicrobials for the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae strains, a systematic review and meta-analysis.
Karampatakis T, Tsergouli K, Lowrie K. Karampatakis T, et al. Microb Pathog. 2023 Jun;179:106090. doi: 10.1016/j.micpath.2023.106090. Epub 2023 Mar 31. Microb Pathog. 2023. PMID: 37004964 Review.
However, novel antimicrobials have been recently launched. Ceftazidime-avibactam (CAZ-AVI) seems one of the most efficient ones. AIM: The aim of the current systematic literature review and meta-analysis is to assess the efficacy and safety of CAZ-AVI compared to ot …
However, novel antimicrobials have been recently launched. Ceftazidime-avibactam (CAZ-AVI) seems one of the most efficient ones. AIM: …
Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
Zhang P, Shi Q, Hu H, Hong B, Wu X, Du X, Akova M, Yu Y. Zhang P, et al. Clin Microbiol Infect. 2020 Jan;26(1):124.e1-124.e4. doi: 10.1016/j.cmi.2019.08.020. Epub 2019 Sep 5. Clin Microbiol Infect. 2020. PMID: 31494252 Free article.
RESULTS: A total of 872 CRKP isolates were collected, and MIC(50) and MIC(90) of CAZ/AVI were 4 and 8 mg/L. The resistant rate of CAZ/AVI was 3.7% (32/872). ...CONCLUSIONS: Resistance against CAZ/AVI in CRKP emerged before clinical use of CAZ/AVI in Ch …
RESULTS: A total of 872 CRKP isolates were collected, and MIC(50) and MIC(90) of CAZ/AVI were 4 and 8 mg/L. The resistant rate of CAZ …
Efficacy and Safety of Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Enterobacterales Bloodstream Infection: a Systematic Review and Meta-Analysis.
Chen Y, Huang HB, Peng JM, Weng L, Du B. Chen Y, et al. Microbiol Spectr. 2022 Apr 27;10(2):e0260321. doi: 10.1128/spectrum.02603-21. Epub 2022 Apr 4. Microbiol Spectr. 2022. PMID: 35377233 Free PMC article.
Studies comparing the clinical outcome of CAZ-AVI with other regimens in CRE BSI were included if they reported data on mortality. ...In this meta-analysis, the efficacy and safety were compared between CAZ-AVI and any other regimens used against CRE infections. The …
Studies comparing the clinical outcome of CAZ-AVI with other regimens in CRE BSI were included if they reported data on mortality. .. …
Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study.
Almangour TA, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, Almohaizeie A, Almuhisen S, Alghaith J, Damfu N, Aljefri D, Alfahad W, Khormi Y, Alanazi MQ, Alsowaida YS. Almangour TA, et al. Antimicrob Agents Chemother. 2023 Aug 17;67(8):e0040523. doi: 10.1128/aac.00405-23. Epub 2023 Jul 5. Antimicrob Agents Chemother. 2023. PMID: 37404159 Free PMC article.
Ceftolozane-tazobactam (C-T) and ceftazidime-avibactam (CAZ-AVI) are two novel antimicrobials that retain activity against resistant Pseudomonas aeruginosa. The comparative effectiveness and safety of C-T versus CAZ-AVI remain unknown. A retrospective, multicenter c …
Ceftolozane-tazobactam (C-T) and ceftazidime-avibactam (CAZ-AVI) are two novel antimicrobials that retain activity against resistant …
Molecular mechanisms underlying bacterial resistance to ceftazidime/avibactam.
Xiong L, Wang X, Wang Y, Yu W, Zhou Y, Chi X, Xiao T, Xiao Y. Xiong L, et al. WIREs Mech Dis. 2022 Nov;14(6):e1571. doi: 10.1002/wsbm.1571. Epub 2022 Jul 26. WIREs Mech Dis. 2022. PMID: 35891616 Free PMC article. Review.
Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel beta-lactamase inhibitor (avibactam) that has been approved by the U.S. ...In this review, the prevalence of CAZ/AVI-resistance bacteria, resistance mechanisms, and selection of detection meth …
Ceftazidime/avibactam (CAZ/AVI), a combination of ceftazidime and a novel beta-lactamase inhibitor (avibactam) that has been approved …
Biotinylated vascular endothelial growth factor(121)-Avi-streptavidin-IRDye800.
Leung K. Leung K. 2009 May 17 [updated 2009 Jul 7]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2009 May 17 [updated 2009 Jul 7]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641650 Free Books & Documents. Review.
Radiolabeled VEGF tracers have been developed for imaging solid tumors and angiogenesis in humans (9-11). Wang et al. (12) fused the Avi peptide (14 amino acids) to the C-terminus of VEGF(121) to allow site-specific biotinylation of the epsilon amine group of a central lys …
Radiolabeled VEGF tracers have been developed for imaging solid tumors and angiogenesis in humans (9-11). Wang et al. (12) fused the Avi …
1,673 results